The effects of amicar and TXA on lumbar spine fusion in an animal model

Jason M. Cuellar, Andrew Yoo, Nick Tovar, Paulo Coelho, Ryo Jimbo, Stefan Vandeweghe, Thorsten Kirsch, Martin Quirno, Thomas J. Errico

Research output: Contribution to journalArticle

Abstract

Study Design. Animal model. Objective. To determine whether aminocaproic acid (Amicar) and tranexamic acid (TXA) inhibit spine fusion volume. Summary of Background Data. Amicar and TXA are antifibrinolytics used to reduce perioperative bleeding. Prior in vitro data showed that antifibrinolytics reduce osteoblast bone mineralization. This study tested whether antifibrinolytics Amicar and TXA inhibit spine fusion. Methods. Posterolateral L4-L6 fusion was performed in 50 mice, randomized into groups of 10, which received the following treatment before and after surgery: (1) saline; (2) TXA 100 mg/kg; (3) TXA 1000 mg/kg; (4) Amicar 100 mg/kg; and (5) Amicar 1000 mg/kg. High-resolution plane radiography was performed after 5 weeks and micro-CT (computed tomography) was performed at the end of the 12-week study. Radiographs were graded using the Lenke scale. Micro-CT was used to quantify fusion mass bone volume. One-way analysis of variance by ranks with Kruskal-Wallis testing was used to com are the radiographical scores. One-way analysis of variance with least significant difference post hoc testing was used to compare the micro-CT bone volume. Results. The average ± standard deviation bone volume/total volume (%) measured in the saline, TXA 100 mg/kg, TXA 1000 mg/kg, Amicar 100 mg/kg, and Amicar 1000 mg/kg groups were 10.8 ± 2.3%, 9.7 ± 2.2%, 13.4 ± 3.2%, 15.5 ± 5.2%, and 17.9 ± 3.5%, respectively. There was a significant difference in the Amicar 100 mg/kg (P < 0.05) and Amicar 1000 mg/kg (P < 0.001) groups compared with the saline group. There was greater bone volume in the Amicar groups compared with the TXA group (P < 0.001). There was more bone volume in the TXA 1000 mg/kg group compared with TXA 100 mg/kg (P < 0.05) but the bone volume in neither of the TXA groups was different to saline (P = 0.49). There were no between-group differences observed using plane radiographical scoring. Conclusion. Amicar significantly "enh nced" the fusion bone mass in a dose-dependent manner, whereas TXA did not have a significant effect on fusion compared with saline control. These data are in contrast to prior in vitro data that antifibrinolytics inhibit osteoblast bone mineralization.

Original languageEnglish (US)
JournalSpine
Volume39
Issue number19
DOIs
StatePublished - Sep 1 2014

Fingerprint

Tranexamic Acid
Aminocaproic Acid
Spine
Animal Models
Antifibrinolytic Agents
Bone and Bones
Physiologic Calcification
Osteoblasts
Analysis of Variance
Cone-Beam Computed Tomography
Radiography

Keywords

  • Amicar
  • antifibrinolytic
  • epsilon aminocaproic acid
  • micro-CT
  • mouse
  • posterolateral spine fusion
  • tranexamic acid
  • TXA

ASJC Scopus subject areas

  • Clinical Neurology
  • Orthopedics and Sports Medicine
  • Medicine(all)

Cite this

Cuellar, J. M., Yoo, A., Tovar, N., Coelho, P., Jimbo, R., Vandeweghe, S., ... Errico, T. J. (2014). The effects of amicar and TXA on lumbar spine fusion in an animal model. Spine, 39(19). https://doi.org/10.1097/BRS.0000000000000488

The effects of amicar and TXA on lumbar spine fusion in an animal model. / Cuellar, Jason M.; Yoo, Andrew; Tovar, Nick; Coelho, Paulo; Jimbo, Ryo; Vandeweghe, Stefan; Kirsch, Thorsten; Quirno, Martin; Errico, Thomas J.

In: Spine, Vol. 39, No. 19, 01.09.2014.

Research output: Contribution to journalArticle

Cuellar, JM, Yoo, A, Tovar, N, Coelho, P, Jimbo, R, Vandeweghe, S, Kirsch, T, Quirno, M & Errico, TJ 2014, 'The effects of amicar and TXA on lumbar spine fusion in an animal model', Spine, vol. 39, no. 19. https://doi.org/10.1097/BRS.0000000000000488
Cuellar, Jason M. ; Yoo, Andrew ; Tovar, Nick ; Coelho, Paulo ; Jimbo, Ryo ; Vandeweghe, Stefan ; Kirsch, Thorsten ; Quirno, Martin ; Errico, Thomas J. / The effects of amicar and TXA on lumbar spine fusion in an animal model. In: Spine. 2014 ; Vol. 39, No. 19.
@article{447768bac852432ead3cde311202c45e,
title = "The effects of amicar and TXA on lumbar spine fusion in an animal model",
abstract = "Study Design. Animal model. Objective. To determine whether aminocaproic acid (Amicar) and tranexamic acid (TXA) inhibit spine fusion volume. Summary of Background Data. Amicar and TXA are antifibrinolytics used to reduce perioperative bleeding. Prior in vitro data showed that antifibrinolytics reduce osteoblast bone mineralization. This study tested whether antifibrinolytics Amicar and TXA inhibit spine fusion. Methods. Posterolateral L4-L6 fusion was performed in 50 mice, randomized into groups of 10, which received the following treatment before and after surgery: (1) saline; (2) TXA 100 mg/kg; (3) TXA 1000 mg/kg; (4) Amicar 100 mg/kg; and (5) Amicar 1000 mg/kg. High-resolution plane radiography was performed after 5 weeks and micro-CT (computed tomography) was performed at the end of the 12-week study. Radiographs were graded using the Lenke scale. Micro-CT was used to quantify fusion mass bone volume. One-way analysis of variance by ranks with Kruskal-Wallis testing was used to com are the radiographical scores. One-way analysis of variance with least significant difference post hoc testing was used to compare the micro-CT bone volume. Results. The average ± standard deviation bone volume/total volume ({\%}) measured in the saline, TXA 100 mg/kg, TXA 1000 mg/kg, Amicar 100 mg/kg, and Amicar 1000 mg/kg groups were 10.8 ± 2.3{\%}, 9.7 ± 2.2{\%}, 13.4 ± 3.2{\%}, 15.5 ± 5.2{\%}, and 17.9 ± 3.5{\%}, respectively. There was a significant difference in the Amicar 100 mg/kg (P < 0.05) and Amicar 1000 mg/kg (P < 0.001) groups compared with the saline group. There was greater bone volume in the Amicar groups compared with the TXA group (P < 0.001). There was more bone volume in the TXA 1000 mg/kg group compared with TXA 100 mg/kg (P < 0.05) but the bone volume in neither of the TXA groups was different to saline (P = 0.49). There were no between-group differences observed using plane radiographical scoring. Conclusion. Amicar significantly {"}enh nced{"} the fusion bone mass in a dose-dependent manner, whereas TXA did not have a significant effect on fusion compared with saline control. These data are in contrast to prior in vitro data that antifibrinolytics inhibit osteoblast bone mineralization.",
keywords = "Amicar, antifibrinolytic, epsilon aminocaproic acid, micro-CT, mouse, posterolateral spine fusion, tranexamic acid, TXA",
author = "Cuellar, {Jason M.} and Andrew Yoo and Nick Tovar and Paulo Coelho and Ryo Jimbo and Stefan Vandeweghe and Thorsten Kirsch and Martin Quirno and Errico, {Thomas J.}",
year = "2014",
month = "9",
day = "1",
doi = "10.1097/BRS.0000000000000488",
language = "English (US)",
volume = "39",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",
number = "19",

}

TY - JOUR

T1 - The effects of amicar and TXA on lumbar spine fusion in an animal model

AU - Cuellar, Jason M.

AU - Yoo, Andrew

AU - Tovar, Nick

AU - Coelho, Paulo

AU - Jimbo, Ryo

AU - Vandeweghe, Stefan

AU - Kirsch, Thorsten

AU - Quirno, Martin

AU - Errico, Thomas J.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Study Design. Animal model. Objective. To determine whether aminocaproic acid (Amicar) and tranexamic acid (TXA) inhibit spine fusion volume. Summary of Background Data. Amicar and TXA are antifibrinolytics used to reduce perioperative bleeding. Prior in vitro data showed that antifibrinolytics reduce osteoblast bone mineralization. This study tested whether antifibrinolytics Amicar and TXA inhibit spine fusion. Methods. Posterolateral L4-L6 fusion was performed in 50 mice, randomized into groups of 10, which received the following treatment before and after surgery: (1) saline; (2) TXA 100 mg/kg; (3) TXA 1000 mg/kg; (4) Amicar 100 mg/kg; and (5) Amicar 1000 mg/kg. High-resolution plane radiography was performed after 5 weeks and micro-CT (computed tomography) was performed at the end of the 12-week study. Radiographs were graded using the Lenke scale. Micro-CT was used to quantify fusion mass bone volume. One-way analysis of variance by ranks with Kruskal-Wallis testing was used to com are the radiographical scores. One-way analysis of variance with least significant difference post hoc testing was used to compare the micro-CT bone volume. Results. The average ± standard deviation bone volume/total volume (%) measured in the saline, TXA 100 mg/kg, TXA 1000 mg/kg, Amicar 100 mg/kg, and Amicar 1000 mg/kg groups were 10.8 ± 2.3%, 9.7 ± 2.2%, 13.4 ± 3.2%, 15.5 ± 5.2%, and 17.9 ± 3.5%, respectively. There was a significant difference in the Amicar 100 mg/kg (P < 0.05) and Amicar 1000 mg/kg (P < 0.001) groups compared with the saline group. There was greater bone volume in the Amicar groups compared with the TXA group (P < 0.001). There was more bone volume in the TXA 1000 mg/kg group compared with TXA 100 mg/kg (P < 0.05) but the bone volume in neither of the TXA groups was different to saline (P = 0.49). There were no between-group differences observed using plane radiographical scoring. Conclusion. Amicar significantly "enh nced" the fusion bone mass in a dose-dependent manner, whereas TXA did not have a significant effect on fusion compared with saline control. These data are in contrast to prior in vitro data that antifibrinolytics inhibit osteoblast bone mineralization.

AB - Study Design. Animal model. Objective. To determine whether aminocaproic acid (Amicar) and tranexamic acid (TXA) inhibit spine fusion volume. Summary of Background Data. Amicar and TXA are antifibrinolytics used to reduce perioperative bleeding. Prior in vitro data showed that antifibrinolytics reduce osteoblast bone mineralization. This study tested whether antifibrinolytics Amicar and TXA inhibit spine fusion. Methods. Posterolateral L4-L6 fusion was performed in 50 mice, randomized into groups of 10, which received the following treatment before and after surgery: (1) saline; (2) TXA 100 mg/kg; (3) TXA 1000 mg/kg; (4) Amicar 100 mg/kg; and (5) Amicar 1000 mg/kg. High-resolution plane radiography was performed after 5 weeks and micro-CT (computed tomography) was performed at the end of the 12-week study. Radiographs were graded using the Lenke scale. Micro-CT was used to quantify fusion mass bone volume. One-way analysis of variance by ranks with Kruskal-Wallis testing was used to com are the radiographical scores. One-way analysis of variance with least significant difference post hoc testing was used to compare the micro-CT bone volume. Results. The average ± standard deviation bone volume/total volume (%) measured in the saline, TXA 100 mg/kg, TXA 1000 mg/kg, Amicar 100 mg/kg, and Amicar 1000 mg/kg groups were 10.8 ± 2.3%, 9.7 ± 2.2%, 13.4 ± 3.2%, 15.5 ± 5.2%, and 17.9 ± 3.5%, respectively. There was a significant difference in the Amicar 100 mg/kg (P < 0.05) and Amicar 1000 mg/kg (P < 0.001) groups compared with the saline group. There was greater bone volume in the Amicar groups compared with the TXA group (P < 0.001). There was more bone volume in the TXA 1000 mg/kg group compared with TXA 100 mg/kg (P < 0.05) but the bone volume in neither of the TXA groups was different to saline (P = 0.49). There were no between-group differences observed using plane radiographical scoring. Conclusion. Amicar significantly "enh nced" the fusion bone mass in a dose-dependent manner, whereas TXA did not have a significant effect on fusion compared with saline control. These data are in contrast to prior in vitro data that antifibrinolytics inhibit osteoblast bone mineralization.

KW - Amicar

KW - antifibrinolytic

KW - epsilon aminocaproic acid

KW - micro-CT

KW - mouse

KW - posterolateral spine fusion

KW - tranexamic acid

KW - TXA

UR - http://www.scopus.com/inward/record.url?scp=84907423690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907423690&partnerID=8YFLogxK

U2 - 10.1097/BRS.0000000000000488

DO - 10.1097/BRS.0000000000000488

M3 - Article

VL - 39

JO - Spine

JF - Spine

SN - 0362-2436

IS - 19

ER -